twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2006
vol. 108
 
Share:
Share:
abstract:
Review article

Pegaptanib sodium in treatment of wet AMD

Magdalena Ulińska
1

  1. Z Katedry i Kliniki Okulistyki II Wydziału Lekarskiego Akademii Medycznej w Warszawie
Online publish date: 2006/12/21
View full text Get citation
 
Taking into consideration that the advanced stage of Age related Macular Degeneration is a very common cause of social blindness and present results of laser photocoagulation, PDT treatment and TTT are not satisfying, it seems to be of huge importance to look for new types of treatment, to improve visual outcomes.

Repeated intravitreal injection of pegaptanib sodium (a VEGF aptamer) is a modern procedure which may not only give stabilization of visual acuity, but it may also lead to the improvement in high percentage. In this paper there is a short update on the epidemiology and the symptoms of the disease and the role of VEGF and its isoforms expression in the development of wet AMD. The presentation of pegaptanib sodium (Macugen®) focus on its mechanism of action. Finally V.I.S.I.O.N. trial results are presented to show encouraging efficacy of the procedure.
keywords:

age related macular degeneration (AMD), choroidal neovascularization, pegaptanib sodium, intravitreal injection

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.